Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-73763989 + nucleos(t)ide analog in hepatitis B and D coinfection
2023-506763-33-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in hepatitis B (HBV), hepatitis D (HDV) and hepatitis D virus coinfection comparing JNJ-73763989 + nucleos(t)ide analog with Placebo + nucleos(t)ide analog with deferred JNJ-73763989 (2 arms). Primary endpoint: Proportion of participants with HDV RNA response and ALT normalization at Week 48. Started Dec 2020; status: completed.
02
Drugs
tomligisiran
03
Conditions
hepatitis B (HBV)hepatitis D (HDV)hepatitis D virus coinfection
Beyond the preview
Go deeper on 2023-506763-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506763-33-00.